NCT03239483View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions
HIV Infections
Interventions
DRUG

Dapivirine gel

Dapivirine gel (0.05%); administered rectally

DRUG

Placebo gel

Universal HEC placebo gel; administered rectally

Trial Locations (3)

11000

Silom Community Clinic CRS, Nonthaburi

15213

University of Pittsburgh CRS, Pittsburgh

35294

Alabama CRS, Birmingham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03239483 - Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults | Biotech Hunter | Biotech Hunter